Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Find Therapeutics’ experienced leadership is developing a novel approach to repair myelin damage in multiple sclerosis, often associated with early visual impairment.
BioCanRx is leading the way in the translation, manufacture and adoption of immunotherapies in Canada to ensure that Canadian patients have access to this powerful therapeutic approach via clinical trials.
The Korea Drug Development Fund supports drug development across all areas of medicine, and here present three companies at the forefront of immunology.
Immunotherapies often fail due to limited response rates or acquired resistance. CNCure Biotech is poised to overcome these problems with a novel bacterial platform to develop treatments for oncology and infectious diseases.
Deliver Biosciences’ platform delivery technology aims to democratize the use of curative therapies by designing nanoparticles that can genetically engineer cells inside patients.
Advance backing of early-stage programs is allowing AbbVie to apply a streamlined approach to support the growth of transformative science, people, and ecosystems.
Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet medical needs.
South Korean nanomedicine company Cenyx Biotech is developing four pipelines of nanozymes for a range of acute and chronic inflammatory diseases. The company’s approach could open a new generation of treatments in immunology and inflammation.
Deals and funding for cell and gene therapy companies have been muted in the past year compared to recent peaks, but emerging technologies that are advancing treatments for autoimmune diseases and in vivo engineering could reinvigorate the field.
Specific Biologics is using its Dualase genome editors to create a pipeline of precision therapeutics that provide solutions for patients with hard-to-treat genetic diseases.
Brainify.AI aims to revolutionize the way mental health disorders are treated by harnessing the power of artificial intelligence/machine learning to identify electroencephalography biomarkers for precision psychiatry.
Through its patient-data-derived Gemini digital twins, Aitia is uncovering the hidden genetic and molecular mechanisms that causally drive human disease, and accelerating the discovery of breakthrough drugs to improve outcomes for neurodegenerative disorders and cancer.
With its artificial intelligence-powered unEarth Rx platform and proprietary fungal collection, Kapoose Creek Bio is discovering the next generation of neuroactive drugs.
With its novel adeno-associated virus discovery platform, Latus Bio is addressing problems associated with high-dose gene therapy for central nervous system diseases, aiming to usher in a new era of safer, more effective, and lower cost treatments.
Thermo Fisher Scientific is leveraging its decades of expertise to help accelerate the efforts of innovative companies that are using oligo- and mRNA-based therapeutics to deliver tangible benefits to patients with unmet needs.
Estonia-based epitranscriptomics company Chemestmed has developed unique proprietary technology that repairs disrupted RNA methylation, opening new avenues for developing drugs to treat neurodegenerative, neuropsychiatric and metabolic disorders.
Spain’s ARTHEx Biotech has developed a dual-mechanism approach to treating the most common adult-onset muscular dystrophy, myotonic dystrophy type 1, setting it apart in a burgeoning blockbuster market.
